替莫唑胺在垂体腺瘤治疗中的应用及进展  

Application and advance of temozolomide in the treatment of pituitary adenomas

作　　者：林益光[1] 刘晓民[1] 

机构地区：[1]天津医科大学第二医院神经外科,300211

出　　处：《中国现代神经疾病杂志》2015年第12期1001-1004,共4页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：天津市自然科学基金资助项目(项目编号:13JCYBJC24000);天津市卫生局科技基金资助项目(项目编号:2011KZ95)~~

摘　　要：垂体腺瘤是临床常见的原发性中枢神经系统肿瘤,其中侵袭性腺瘤和垂体腺癌因其侵袭性生长的病理生理学特点仍是目前神经外科治疗之难点,需手术切除病灶辅助放射治疗和药物化疗。近年来,由于替莫唑胺对功能性垂体腺瘤、侵袭性垂体腺瘤和垂体腺癌的治疗取得进展,使其颇受临床关注,尤其是O6-甲基鸟嘌呤-DNA甲基转移酶可否作为判断替莫唑胺疗效的指标,成为烷化剂化疗药物之研究热点。Pituitary adenoma is a common primary tumor in central nervons system. The aggressivepituitary adenomas show invasive characteristics with higher recurrence rate and worse prognosis, whichnormally need the comprehensive therapy of surgery, radiotherapy and chemical medications. The therapyof aggressive pituitary adenomas by temozolomide and whether O6-methylguanine-DNA methyltransferase（MGMT） could predict the curative effect of temozolomide have become hot spots in recent years. Thisreview intends to illustrate the advance of the therapy of aggressive pituitary adenomas by temozolomide.

关 键 词：垂体肿瘤 替莫唑胺(非MeSH词) O(6)-甲基鸟嘌呤DNA甲基转移酶 综述 

分 类 号：R736.4[医药卫生—肿瘤]